This e-newsletter explores abstracts that focus on innovations in treatment strategies, biomarker-driven approaches, and real-world evidence, reinforcing the critical role of CD38-targeted therapies in improving outcomes for MM patients.

This e-newsletter features recent developments and key clinical trial data suggesting that the role of CD38-targeted therapies is continuing to evolve, and has the potential to reshape clinical practice even further.

This e-newsletter reviews key findings from the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting relative to CRS and ICANS associated with novel immunotherapies for MM, providing crucial insights into predicting, recognizing, and managing these immunotherapy-related adverse events.

This e-newsletter features summaries of selected key abstracts from the ASCO Annual Meeting that collectively emphasize the evolving role of anti-CD38 monoclonal antibodies in multiple myeloma, further establishing these agents as critical components of frontline and subsequent treatment strategies.

Dr. Ajai Chari will review clinical implications of minimal residual disease (MRD) and its use in guiding treatment decisions and shares how risk-adapted treatment may benefit patients.

Dr. Sagar Lonial will discuss treatment sequencing and approaches, as well as the significance of giving patients the best results without increasing toxicity and side effects when adding more drugs.

In this activity, Dr. Caitlin Costello will focus on safety, tolerability, and adverse event considerations in newly diagnosed multiple myeloma.

In this activity, Dr. Amrita Krishnan will summarize clinical data that supports the use of triplet and quadruplet regimens in transplant-eligible patients.

In this activity, Dr. Saad Z. Usmani will focus on outlining practical strategies for implementing new and evolving standards of care into the treatment of transplant-ineligible patients with NDMM.

Join Dr. Sagar Lonial as he reviews recent developments in the treatment of newly diagnosed multiple myeloma (NDMM). Included in this discussion are findings from the DETERMINATION, GRIFFIN, CASSIOPEIA, ALCYON, and COLUMBA trials, among others, that may inform treatment for both transplant-eligible and transplant-ineligible NDMM.